-
Mashup Score: 0
Retrospective study finds no reduction in opioid use vs conventional medical management
Source: www.medpagetoday.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0
Title: Spinal Cord Stimulation Trialing: Is Trialing Predictive of Short, Intermediate, and Long-term Pain Outcomes? Introduction: Spinal cord stimulation (SCS) is a proven, effective treatment for chronic neuropathic back and limb pain. Recently, emphasis has been placed on methods to improve long-term efficacy and reduce explant rates. •SCS trial is used as a prognostic tool. • Successful…
Source: epostersonline.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0
/PRNewswire/ — Theranica, a prescribed digital therapeutics company developing advanced digitally-connected neuromodulation devices for migraine and other…
Source: www.prnewswire.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0New version of implanted neuromodulation device for HF launched - 2 year(s) ago
CVRx announced it has launched a next-generation version of its neuromodulation device to treat HF symptoms. The device (Barostim Neo2 IPG) is the second generation of the first FDA-approved neuromodulation system to treat HF, according to a press release issued by the company.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0New version of implanted neuromodulation device for HF launched - 2 year(s) ago
CVRx announced it has launched a next-generation version of its neuromodulation device to treat HF symptoms. The device (Barostim Neo2 IPG) is the second generation of the first FDA-approved neuromodulation system to treat HF, according to a press release issued by the company.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0New version of implanted neuromodulation device for HF launched - 2 year(s) ago
CVRx announced it has launched a next-generation version of its neuromodulation device to treat HF symptoms. The device (Barostim Neo2 IPG) is the second generation of the first FDA-approved neuromodulation system to treat HF, according to a press release issued by the company.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Bay Area female-led medtech picks $15M to develop new treatments for patients with complex diseases — TFN - 2 year(s) ago
Boomerang Medical, a women-led bioelectronic medicine startup, has closed $15 million in Series A funding.
Source: Tech Funding NewsCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Neurology journals - 2 year(s) ago
We proudly present our journals in Neurology.
Source: www.elsevier.comCategories: Latest Headlines, NeurologyTweet-
Learn about all of our journals in Neurology here: https://t.co/3oC9GmWXR5 #neurology #brain #nervoussystem #neuroimmunology #neuroscience #pediatricneurology #neurosurgery #neuropathology #neuroimaging #neurooncology #neurophysiology #neuroendocrinology #neuromodulation #sleep https://t.co/fT5WqIfRb3
-
-
Mashup Score: 0Neuromodulation Journal - 2 year(s) ago
Neuromodulation: Technology at the Neural Interface is the preeminent journal in the area of neuromodulation.
Source: www.neuromodulation.comCategories: Addiction Medicine, Latest HeadlinesTweet
-
Mashup Score: 1Neuromodulation Journal - 2 year(s) ago
Neuromodulation: Technology at the Neural Interface is the preeminent journal in the area of neuromodulation.
Source: www.neuromodulation.comCategories: Latest Headlines, NeurologyTweet
Spinal Cord Stimulators #SCS for #ChronicPain May Not Live Up to the Hype #neuromodulation https://t.co/X5BcDDtDNW